{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:03:42Z","timestamp":1789549422975,"version":"build-2803163510"},"reference-count":42,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:00:00Z","timestamp":1138147200000},"content-version":"vor","delay-in-days":1516,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2001,12]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> The Breast Cancer Prevention Trial (P\u20101: BCPT) of the National Surgical Adjuvant Breast and Bowel Project (NSABP) randomized 13,388 women, \u226535 years of age, at increased risk for breast cancer [\u22651.66% by Gail model criteria or with a history of lobular carcinoma <jats:italic>in situ<\/jats:italic> (LCIS)] to 5 years of tamoxifen or placebo. A 49% reduction (<jats:styled-content><jats:italic>P<\/jats:italic> &lt; 0.00001<\/jats:styled-content>) in invasive breast cancers occurred, 175 with placebo versus 89 with tamoxifen, mainly among estrogen receptor (ER)\u2010positive tumors (130 with placebo vs. 41 with tamoxifen). The major toxicities of tamoxifen were endometrial cancer (15 with placebo vs. 36 with tamoxifen) and thromboembolic disease, both predominantly in women who were \u226550 years old. Ramifications emerging from the P\u20101 results regarding the efficacy and toxicities of preventive tamoxifen include the following: (1) Does tamoxifen induce more virulent breast cancers? (2) Does tamoxifen induce more virulent endometrial cancers? (3) Tamoxifen is especially efficacious in reducing breast cancer risk in LCIS (18 invasive breast cancers with placebo vs. 8 with tamoxifen group) and atypical ductal hyperplasia (AH) (23 invasive breast cancers with placebo vs. 3 with tamoxifen). (4) Does tamoxifen reduce breast cancer risk in women at increased risk due to genetic mutations? (5) How can we prevent tamoxifen\u2010resistant breast cancers? (6) What do the BCPT results tell us about who should take preventive tamoxifen? In its ongoing effort to lower the incidence of breast cancer, the NSABP is now implementing its second breast cancer prevention trial, the Study of Tamoxifen and Raloxifene (STAR), which is comparing the two agents with regard to efficacy and toxicity.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2001.tb04007.x","type":"journal-article","created":{"date-parts":[[2010,7,21]],"date-time":"2010-07-21T00:21:44Z","timestamp":1279671704000},"page":"99-108","source":"Crossref","is-referenced-by-count":39,"title":["The Role of Tamoxifen in Breast Cancer Prevention"],"prefix":"10.1111","volume":"949","author":[{"given":"NORMAN","family":"WOLMARK","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BARBARA K.","family":"DUNN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1371"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/81.24.1879"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)91141-0"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.10.1740"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.7.527"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92692-1"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1994.1271"},{"issue":"1","key":"e_1_2_5_9_2","first-page":"27","article-title":"Endometrial cancer and tamoxifen","volume":"19","author":"Barakat R.R.","year":"1999","journal-title":"Primary Care Cancer"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.9.645"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(97)00591-7"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.485"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.22.1850"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506153322401"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0029-7844(94)00383-O"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-2-199907200-00009"},{"key":"e_1_2_5_17_2","unstructured":"Winer E.P. M. Morrow C.K. Osborne & J.R. Harris. 2001. Malignant tumors of the breast.InCancer: Principles and Practice of Oncology. Sixth edition pp. 1651\u20101717. Lippincott\/Williams & Williams. Philadelphia."},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198501173120303"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7545954"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/378789a0"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2270482"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.6.1504.bloodjournal8561504"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615049"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.10.3698.bloodjournal88103698"},{"key":"e_1_2_5_25_2","unstructured":"Prentice R. 1995. Experimental methods in cancer prevention research.InCancer Prevention and Control pp. 80\u201081. Dekker. New York."},{"key":"e_1_2_5_26_2","first-page":"4743","article-title":"Prevention of cancer in the next millennium: report of the Chemoprevention Working Group to the American Association for Cancer Research","volume":"59","author":"Chemoprevention Working Group","year":"1999","journal-title":"Cancer Res."},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.5.1632"},{"key":"e_1_2_5_28_2","unstructured":"Zeneca. 1998. Tamoxifen prescribing information [package insert]. Zeneca. Wilmington DE."},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)85012-5"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04394-3"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)85002-2"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.8.730"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05036-9"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901143400201"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.17.1475"},{"issue":"2","key":"e_1_2_5_36_2","first-page":"11","article-title":"The Breast Cancer Prevention Trial, tamoxifen, and the woman at high risk for breast cancer","volume":"19","author":"Wolmark N.","year":"1999","journal-title":"Primary Care Cancer"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.21.1829"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1939"},{"key":"e_1_2_5_39_2","first-page":"604","article-title":"Probability at the bedside: the knowing of chances or the chances of knowing? Ann","volume":"130","author":"Goodman S.N.","year":"1999","journal-title":"Intern. Med."},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901143400211"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.23.2189"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.7.637"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199712043372301"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2001.tb04007.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2001.tb04007.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T02:04:51Z","timestamp":1695607491000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2001.tb04007.x"}},"subtitle":["Issues Sparked by the NSABP Breast Cancer Prevention Trial (P\u20101)"],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["10.1111\/j.1749-6632.2001.tb04007.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2001.tb04007.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}